On October 18, 2021 Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, reported the appointment of Hamid Erfanian as Chief Executive Officer (Press release, Enzo Biochem, OCT 18, 2021, View Source [SID1234591445]). Following the succession plan announced in March and the engagement of Korn Ferry, Dr. Elazar Rabbani remains Chairperson of the Board of Directors and will assume the role of Chief Scientific Officer of the Company. Mr. Erfanian brings over 28 years of experience as a seasoned healthcare executive specializing in the diagnostic, medical devices, and life sciences industry. His demonstrated track record of implementing commercial strategies and building high performing teams at both global and smaller firms provides the ideal balance of qualifications to support Enzo as it evolves under the guidance of new leadership. Mr. Erfanian’s employment will begin in early November.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I am thrilled to be joining Enzo, an established innovator in the diagnostics space, at this pivotal stage of development," stated Mr. Erfanian. "I firmly believe the Company’s GENFLEX platform, and its broad menu of molecular products are very well positioned to continue to serve the diagnostics market. The vision of new molecular product development and service expansion into new clinical settings is a vital mission as the Company evolves in this post pandemic environment. I look forward to leading these efforts and the Enzo executive management team."
Mr. Erfanian was most recently Chief Commercial Officer of EUROIMMUN, a PerkinElmer Company. He previously served as Chief Executive Officer of its US subsidiary, a position he held from June 2014 through August 2021, where he was responsible for growing sales by more than 20-fold in five years. EUROIMMUN is a world leader in the field of medical diagnostics. In his role, he commercialized several diagnostic product offerings including those that enable the detection of antibodies associated with autoimmune and infectious diseases. Prior to EUROIMMUN, Mr. Erfanian held executive and senior positions at several notable diagnostics companies including Diagnostica Stago, Beckman Coulter, and Abbott Laboratories. Earlier in his career, Mr. Erfanian worked at leading diagnostic laboratory testing companies, Quest Diagnostics and Laboratory Corporation of America. He received his Bachelor’s Degree in Science and Mathematics from North Dakota State University and a Masters of Business Administration from the Cox School of Business at Southern Methodist University.
"The Board is excited that Mr. Erfanian is joining the Company to lead us through this next stage of commercialization and growth as we capitalize on our molecular diagnostics platforms for central lab and point of care uses," stated Dr. Rabbani, Enzo’s Chairperson. "We have the deepest confidence that Mr. Erfanian will leverage Enzo’s proprietary and innovative platforms, strong asset base, and approximately 475 global patents. He joins the Company at an exciting juncture of growth and opportunity."